Value in Health  by unknown
Value in Health
VOLUME 9
Issue 1, January/February 2006
EMPIRICAL
1 Systematic Screening for Chlamydia trachomatis: Estimating Cost-Effectiveness Using Dynamic 
Modeling and Dutch Data
Robin de Vries, MSc, Jan E.A.M. van Bergen, MD, Lolkje T.W. de Jong-van den Berg, PhD, PharmD, 
Maarten J. Postma, PhD, for the PILOT-CT Study Group 
12 Economic Evaluation of Voriconazole versus Conventional Amphotericin B in the Treatment 
of Invasive Aspergillosis in Germany
Jeroen P. Jansen, PhD, Winfried V. Kern, MD, Oliver A. Cornely, MD, Meinolf Karthaus, MD,  
Markus Ruhnke, MD, Andrew J. Ullmann, MD, MPH, Ansgar Resch, MD, MPH
24 The New Injury Severity Score: Better Prediction of Functional Recovery after 
Musculoskeletal Injury
Alasdair G. Sutherland, MD (Hons), FRCSEd (Tr&Orth), Andrew T. Johnston, MRCSEd,  
James D. Hutchison, PhD
28 Pramipexole versus Levodopa in Patients with Early Parkinson’s Disease: Effect on Generic 
and Disease-Speciﬁc Quality of Life
Katia Noyes, PhD, MPH, Andrew W. Dick, PhD, Robert G. Holloway, MD, MPH, the Parkinson Study 
Group
39 Discrepancies between Patient-Reported Outcomes and Clinician-Reported Outcomes in 
Chronic Venous Disease, Irritable Bowel Syndrome, and Peripheral Arterial Occlusive 
Disease
Olivier Chassany, MD, PhD, Philippe Le-Jeunne, MD, Martin Duracinsky, MD, MSc,  
Marie-Sophie Schwalm, MSc, Marc Mathieu, MD 
47 Measurement of HRQL Using EQ-5D in Patients with Type 2 Diabetes Mellitus in Japan
Hiroyuki Sakamaki, MBA, Shunya Ikeda, DMedSci, MD, Naoki Ikegami, DMedSci, MD,  
Yasuko Uchigata, PhD, MD, Yasuhiko Iwamoto, PhD, MD, Hideki Origasa, PhD, Toshiki Otani, MD,  
Yoichi Otani, MD
METHODOLOGY
54 Developing Better Economic Models of Osteoporosis: Considerations for the Calculation of 
the Relative Risk of Fracture
Dennis M. Black, PhD, Lisa Palermo, MA, Daniel T. Grima, MSc
59 A Comparison of Depressive Symptoms in Stroke and Primary Care:  Applying Rasch Models 
to Evaluate the Center for Epidemiologic Studies-Depression Scale
A. Simon Pickard, PhD, Mehul R. Dalal, PhD, Donald M. Bushnell, MA
Issue 2, March/April 2006
COMMENTARY
65 Determinants of Health Economic Decisions in Actual Practice: The Role of Behavioral 
Economics
EMPIRICAL
68 Cost-Effectiveness of Fondaparinux Compared with Enoxaparin as Prophylaxis against Venous 
Thromboembolism in Patients Undergoing Hip Fracture Surgery
Sean D. Sullivan, PhD, Louis Kwong, MD, Edith Nutescu, PharmD
A412 Volume Table of Contents
77 Cost-Effectiveness of Olanzapine as First-Line Treatment for Schizophrenia: Results from a 
Randomized, Open-Label, 1-Year Trial
Sandra L. Tunis, PhD, Douglas E. Faries, PhD, Allen W. Nyhuis, MS, Bruce J. Kinon, MD,  
Haya Ascher-Svanum, PhD, Ralph Aquila, MD
90 Performance of the EQ-5D in Patients with Irritable Bowel Syndrome
Donald M. Bushnell, MA, Mona L. Martin, RN, MPA, Jean-François Ricci, PhD, Andrea Bracco, MSc
98 Validation of Electronic Data Capture of the Irritable Bowel Syndrome—Quality of Life 
Measure, the Work Productivity and Activity Impairment Questionnaire for Irritable Bowel 
Syndrome and the EuroQol
Donald M. Bushnell, MA, Margaret C. Reilly, MPH, Carmen Galani, MD, Mona L. Martin, RN, MPA,  
Jean-François Ricci, PhD, Donald L. Patrick, PhD, Christopher R. McBurney, PharmD
METHODOLOGY
106 A Primer on Dynamic Optimization and Optimal Control in Pharmacoeconomics
John A. Vernon, PhD, W. Keener Hughen, PhD
114 The Instrumental Variable Method to Study Self-Selection Mechanism: A Case of Inﬂuenza 
Vaccination
Byung-Kwang Yoo, MD, PhD, Kevin D. Frick, PhD
123 Incorporating Direct and Indirect Evidence Using Bayesian Methods: An Applied Case Study 
in Ovarian Cancer
Susan Grifﬁn, MSc, Laura Bojke, MSc, Caroline Main, MSc, Stephen Palmer, MSc
132 Psychometric Evaluation of a New Questionnaire Measuring Treatment Satisfaction in  
Hypothyroidism: The ThyTSQ
Carolyn McMillan, PhD, Clare Bradley, PhD, Salman Razvi, MRCP, Jolanta Weaver, PhD, FRCP
BOOK REVIEW
140 Using Cost-Effectiveness Analysis to Improve Health Care: Opportunities and Barriers by  
Peter J. Neumann
C. Daniel Mullins, PhD
Issue 3, May/June 2006
EDITORIALS
141 Where’s the Value in Health Care?
Joel W. Hay, PhD
144 Substantial Returns to Health-Care Spending: But Do We Spend Too Little or Too Much?
Martin J. Buxton, BA (Soc Sci)
POLICY AND APPLICATION
146 The Return on Investment in Health Care: From 1980 to 2000
Bryan R. Luce, PhD, MBA, Josephine Mauskopf, PhD, Frank A. Sloan, PhD, Jan Ostermann, PhD,  
L. Clark Paramore, MSPH
157 Economic Evaluation in Health Care: The Point of View of Informed Physicians
Giovanni Fattore, MSc, Aleksandra Torbica, MSc
COMMENTARY
168 Bringing Health Economic Modeling to the 21st Century
David Eddy, PhD, MD
179 The Future of Health Economic Modeling: Have We Gone Too Far or Not Far Enough?
A. Mark Fendrick, MD
181 What Decision-Makers Want and What They Have Been Getting
Maurice McGregor, MD
EMPIRICAL
186 Health Resource Utilization and Medical Care Cost of Acute Care Elderly Unit Patients
Ravishankar Jayadevappa, PhD, Sumedha Chhatre, PhD, Mark Weiner, MD,  
Donna B. Raziano MD, MBA
Volume Table of Contents A413
193 Cost of Hypoglycemia in Patients with Type 2 Diabetes in Sweden
Linus Jönsson, MD, PhD, Björn Bolinder, MD, Jonas Lundkvist, RPh, PhD
199 Linguistic Validation of the US Spanish Work Productivity and Activity Impairment 
Questionnaire, General Health Version
Mary C. Gawlicki, MBA, Margaret C. Reilly, MPH, Ana Popielnicki, BA, Kate Reilly, MA
 ISPOR ELEVENTH ANNUAL INTERNATIONAL MEETING
 CONTRIBUTED PRESENTATION ABSTRACTS
A1 CONTRIBUTED PODIUM PRESENTATIONS
A24 CONTRIBUTED POSTER PRESENTATIONS
A174 DISCLOSURE INFORMATION
A180 ABSTRACT INDEX
Issue 4, July/August 2006
POLICY AND APPLICATION
205 Are Australians Able to Access New Medicines on the Pharmaceutical Beneﬁts Scheme in a 
More or Less Timely Manner? An Analysis of Pharmaceutical Beneﬁts Advisory Committee 
Recommendations, 1999–2003
Michael J. Wonder, BSc (Hons), BPharm, A. Munro Neville, MBBS, MSc, MBA,  
Richard Parsons, MSc, PhD
213 Trends in the Measurement of Health Utilities in Published Cost-Utility Analyses
Carmen A. Brauer MD, MSc, FRCSC, Allison B. Rosen MD, ScD, Dan Greenberg PhD,  
Peter J. Neumann ScD
EMPIRICAL
219 An Economic Evaluation of Two Ototopical Treatments for Acute Otitis Media in 
Tympanostomy Tube Patients
Peter S. Roland, MD, Curtis R. Waycaster, PhD, G. Michael Wall, PhD, Jeffrey D. Glass, PharmD
227 Estimating the Cost-Effectiveness of Fluticasone Propionate for Treating Chronic Obstructive 
Pulmonary Disease in the Presence of Missing Data
Andrew H. Briggs, DPhil, Greta Lozano-Ortega, MSc, Sally Spencer, PhD, Geraldine Bale, RCN,  
Michael D. Spencer, MSc, P. Sherwood Burge, MD
236 Managing Meningococcal Disease in the United States: Hospital Case Characteristics and 
Costs by Age
Judith A. O’Brien, RN, J. Jaime Caro, MDCM, Denis Getsios, BA
METHODOLOGY
244 Probabilistic Analysis and Computationally Expensive Models: Necessary and Required?
Susan Grifﬁn, MSc, Karl Claxton, PhD, Neil Hawkins, PhD, Mark Sculpher, PhD
253 Indirect Costs and Cost-Effectiveness Analysis
Richard Ernst, PhD
262 Comparing the EQ-5D and the SF-6D Descriptive Systems to Assess Their Ceiling Effects in 
the US General Population
Murtuza Bharmal, PhD, Joseph Thomas III, PhD
SHORT NOTES
272 Fraction of Nursing Home Admissions Attributable to Urinary Incontinence
Alan Morrison, PhD, Richard Levy, PhD
CORRESPONDENCE
275 Applying the Grid Computation in Long-Term Retrospective Health Insurance Data Analysis
Yung-Tai Yen, MS, Yu-Chuan Li, MD, PhD, Ming-Chin Lin, MD, Chien-Yeh Hsu, PhD
276 Is Rosuvastatin Really a More Efﬁcient Therapeutic Option than Atorvastatin?
Javier Soto, MD, PhD, Jaime Fernandez de Bobadilla, MD
277 Formulary Decision-Making Should Rely on the Best Available Evidence
Joshua S. Benner, PharmD, ScD, Timothy W. Smith, David Klingman, PhD, Jonothan C. Tierce, CPhil, 
C. Daniel Mullins, PhD, Ned Pethick, John C. O’Donnell, PhD
A414 Volume Table of Contents
Issue 5, September/October 2006
POLICY AND APPLICATION
281 Analytic Considerations in Economic Evaluations of Multinational Cardiovascular Clinical 
Trials
Frank M. Torti, Jr., BA, Shelby D. Reed, PhD, Kevin A. Schulman, MD
EMPIRICAL
292 Implantable or External Deﬁbrillators for Individuals at Increased Risk of Cardiac Arrest: 
Where Cost-Effectiveness Hits Fiscal Reality
Peter Cram, MD, MBA, David Katz, MD, MSc, Sandeep Vijan, MD, MS, David M. Kent, MD, MS,  
Kenneth M. Langa, MD, PhD, A. Mark Fendrick, MD 
METHODOLOGY
303 Eliciting Stated Preferences for Health-Technology Adoption Criteria Using Paired 
Comparisons and Recommendation Judgments
F. Reed Johnson, PhD, Martin Backhouse, PhD
312 Development of a Smiling Touchscreen Multimedia Program for HRQoL Assessment in 
Subjects with Varying Levels of Literacy
Julian Thumboo, FRCP(Edin), Hwee-Lin Wee, PhD, Yin-Bun Cheung, PhD, David Machin, PhD,  
Nan Luo, PhD, Kok-Yong Fong, FRCP(Edin)
320 Validation of the Revised 10-Item HIV Treatment Satisfaction Questionnaire Status Version 
and New Change Version
Alison Woodcock, PhD, C. Psychol, AFBPsS, Clare Bradley, PhD, C. Psychol, FBPsS, FRSM
334 Analyses of Cost Data in Economic Evaluations Conducted Alongside Randomized Controlled 
Trials
Jalpa A. Doshi, PhD, Henry A. Glick, PhD, Daniel Polsky, PhD
341 A Dollar Is a Dollar Is a Dollar—or Is It?
Werner B. F. Brouwer, PhD,  N. Job A. van Exel, MSc, Rob M. P. M. Baltussen, PhD,  
Frans F. H. Rutten, PhD 
348 Assessing the Direct Costs of Treating Nonvalvular Atrial Fibrillation in the United States
Karin S. Coyne, PhD, MPH, Clark Paramore, MSPH, Susan Grandy, PhD, MBA, Marco Mercader, MD, 
Matthew Reynolds, MS, MD, Peter Zimetbaum, MD
CORRESPONDENCE
357 Cost-Effectiveness of Olanzapine as a First-Line Treatment: A Comment
Anirban Basu, PhD
358 Cost-Effectiveness of Olanzapine as a First-Line Treatment: A Response to Comment
Sandra L. Tunis, PhD, Douglas E. Faries, PhD, Allen W. Nyhuis, MS, Bruce J. Kinon, MD,  
Haya Ascher-Svanum, PhD, Ralph Aquila, MD
359 ERRATUM
Issue 6, November/December 2006
EMPIRICAL
361 Impact of Rofecoxib Withdrawal on Cyclooxygenase-2 Utilization among Patients with and 
without Cardiovascular Risk
Patrick Thiebaud, PhD, Bimal V. Patel, PharmD, MS, Michael B. Nichol, PhD   
369 Estimating the Cost-Effectiveness of Quality-Improving Interventions in Oral Anticoagulation 
Management within General Practice
Neree Claes, MD, PhD, Karen Moeremans, MD, Buntinx Frank, MD, PhD, Arnout Jef, PhD,  
Vermylen Jos, MD, PhD, Van Loon Herman, MD, PhD, Annemans Lieven, PhD
METHODOLOGY
377 Too Much Ado about Propensity Score Models? Comparing Methods of Propensity Score 
Matching
Onur Baser, PhD
Volume Table of Contents A415
386 Longitudinal Metric Properties of Disability Rating Scales for Parkinson’s Disease
Pablo Martinez-Martin, MD, PhD, Luis Prieto, MSc, PhD, Maria João Forjaz, MSc, PhD
394 Integrating the Patient’s Perspective into Device Evaluation Trials
Nancy Kline Leidy, PhD, Kathleen Beusterien, MPH, Erin Sullivan, PhD, Randel Richner, MPH,  
Neal I. Muni, MD, MSPH
ISPOR NINTH ANNUAL EUROPEAN CONGRESS
 CONTRIBUTED PRESENTATION ABSTRACTS
A187 CONTRIBUTED PODIUM PRESENTATIONS
A208 CONTRIBUTED POSTER PRESENTATIONS
A394 DISCLOSURE INFORMATION
A401 ABSTRACTS INDEX
A410 ERRATUM
A411 VOLUME TABLE OF CONTENTS
